BeyondSpring (NASDAQ:BYSI) Stock Price Down 4.8% – Time to Sell?

Posted by Latisha Jones on Jun 14th, 2026

Shares of BeyondSpring Inc. (NASDAQ:BYSI – Get Free Report) were down 4.8% on Friday . The stock traded as low as $1.56 and last traded at $1.57. Approximately 14,427 shares changed hands during trading, a decline of 42% from the average daily volume of 24,960 shares. The stock had previously closed at $1.65.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d+)” rating on shares of BeyondSpring in a report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, BeyondSpring presently has an average rating of “Sell”.

Read Our Latest Report on BeyondSpring

BeyondSpring Trading Down 4.8%

The stock’s 50-day moving average is $1.61 and its 200-day moving average is $1.65. The stock has a market cap of $64.56 million, a price-to-earnings ratio of -11.21 and a beta of 0.43.

BeyondSpring (NASDAQ:BYSI – Get Free Report) last posted its earnings results on Wednesday, May 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.49.

Institutional Trading of BeyondSpring

A hedge fund recently bought a new stake in BeyondSpring stock. State Street Corp acquired a new stake in BeyondSpring Inc. (NASDAQ:BYSI – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 231,120 shares of the company’s stock, valued at approximately $377,000. State Street Corp owned approximately 0.57% of BeyondSpring as of its most recent SEC filing. Hedge funds and other institutional investors own 40.29% of the company’s stock.

About BeyondSpring

(Get Free Report)

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.